{"id":"W4402565677","doi":"10.1016/j.annonc.2024.08.2296","title":"LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; Chemotherapy; Oncology; Interim; Lung cancer; Internal medicine; Chemotherapy regimen; Cancer research; Cancer; Adenocarcinoma; ROS1","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006948314,0.0006399912,0.001434901,0.0003172196,0.0002398663,0.0009892042,0.0005156958,0.000699979,0.003723541],"category_scores_gemma":[0.0008337887,0.0001984631,0.002020203,0.0002710127,0.0003279887,0.0008648785,0.0003875,0.001938594,0.0004203259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001085096,"about_ca_system_score_gemma":0.0009926175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001823204,"about_ca_topic_score_gemma":0.007233445,"domain_scores_codex":[0.999681,0.00008234136,0.00001676472,0.00005724119,0.00002434103,0.0001383842],"domain_scores_gemma":[0.9996099,0.00008656901,0.00006352524,0.00002635544,0.0000134561,0.0002002838],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6774575,0.007439313,0.03754464,0.0006292159,0.004192813,0.0005895267,0.0002142102,0.005725114,0.008481844,0.0009348523,0.007716325,0.2490747],"study_design_scores_gemma":[0.1554959,0.4200169,0.3634687,0.0007411856,0.01373039,0.00176198,0.0007536708,0.01352719,0.007270692,0.004180014,0.01887124,0.0001821446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991367,0.004299854,0.0001097263,0.0005387246,0.0002724607,0.0000702116,0.0005306341,0.00002482597,0.002786404],"genre_scores_gemma":[0.9943639,0.00188587,0.0001553544,0.000464969,0.0002010985,0.00008500038,0.0009708102,0.00001339053,0.001859677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003723541,"threshold_uncertainty_score":0.01245648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02227508475015781,"score_gpt":0.4032019958116301,"score_spread":0.3809269110614723,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}